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Abstract
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecological malignancy in 
the developed world accounting for 4 percent of deaths from cancer in women1. We performed a 
three-phase genome-wide association study of EOC survival in 8,951 EOC cases with available 
survival time data, and a parallel association analysis of EOC susceptibility. Two SNPs at 
19p13.11, rs8170 and rs2363956, showed evidence of association with survival (overall P=5×10−4 
and 6×10−4), but did not replicate in phase 3. However, the same two SNPs demonstrated genome-
wide significance for risk of serous EOC (P=3×10−9 and 4×10−11 respectively). Expression 
analysis of candidate genes at this locus in ovarian tumors supported a role for the BRCA1 
interacting gene C19orf62, also known as MERIT40, which contains rs8170, in EOC development.
Factors related to tumor aggressiveness, response to therapy, and underlying patient health 
are major predictors of survival in EOC. Germline genetic variation could impact every step 
in the process from the likelihood of secondary mutational events to host tissue tolerance of 
a metastatic lesion and treatment response. Evidence for the role of germline genetics comes 
from the observations that rare EOC predisposition-alleles of BRCA1 and BRCA2 are 
associated with improved overall survival following a diagnosis of EOC2, 3. Many studies 
have investigated the association between common genetic variation in candidate genes and 
EOC survival, but no positive findings have been convincingly replicated. GWAS have 
successfully identified common genetic variants influencing a spectrum of phenotypes4; but, 
to date, there are no published reports of GWAS for cancer survival outcomes.
We conducted a three-phase GWAS to identify SNPs associated with variation in the time 
from invasive EOC diagnosis to death (Supplementary tables 1 and 2). Genotyping was 
carried out in parallel with a multi-phase GWAS of EOC susceptibility5. Phase 1 comprised 
1,768 cases with invasive EOC from four UK studies. Survival time data, predominantly 
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through routine notification of deaths through the Office of National Statistics, was available 
for 86 percent of cases. Controls were taken from two studies previously used as part of a 
GWAS for other phenotypes, the UK 1958 Birth Cohort and the UK Colorectal Control 
Cohort. Cases were genotyped using the Illumina Infinium 610K array and controls were 
genotyped using the similar 550k Illumina array5–7.
Association between SNP genotypes and survival were evaluated using a 1 degree of 
freedom trend test based on the Cox model (see methods). The 4,649 SNPs showing the 
strongest evidence for association with EOC survival were selected for genotyping in phase 
2 together with 22,790 SNPs selected for the susceptibility study and 800 SNPs that reported 
on ancestry. Phase 2 comprised 4,238 cases and 4,810 controls from ten different studies 
across the USA, Europe and Australia; SNPs were genotyped using a custom Illumina 
iSelect array. The majority of cases (80 percent) had survival time data available through a 
variety of sources including death certificate flagging and medical records. Finally, we 
genotyped the three SNPs most strongly associated with survival - rs1125436, rs8170 and 
rs2363956 - in a phase 3 analysis that included 4,501 cases (of which 4,076 had survival 
time data) and 6,021 controls from twenty two additional studies that are part of the Ovarian 
Cancer Association Consortium (OCAC). The SNPs rs10426843 and rs8100241 that 
correlate perfectly with rs8170 and rs2363956, respectively, were included as proxies in the 
event of assay failure. We also genotyped thirty SNPs from the top nine loci from the 
analysis of susceptibility8. Genotyping of rs2363956 was poor for phase 3 studies genotyped 
by iPlex (see Methods and Supplementary note) and genotype data for the surrogate marker 
was used in analyses.
Characteristics of the cases by study phase are shown in Supplementary table 1. Cases from 
all three phases provided 21,127 person-years of follow-up; 3,358 deaths occurred within 
five years following diagnosis of EOC in the combined dataset. There was little evidence of 
any general inflation of the survival test statistics in either phase 1 or phase 2 (estimated 
inflation factor phase 1 λ1000 =0.99, phase 2 λ1000 =0.99) (Supplementary figure 1). In the 
analysis of the combined phase 1 and 2 data the SNP most strongly associated with risk of 
death was rs1125436 at 13q32 (HR=1.22, 95% CI 1.12–1.32, P=3×10−6). There was no 
association of this SNP with EOC susceptibility (P=0.57). The next most strongly associated 
locus with survival was at 19p13, containing rs8170 (risk allele t) and rs2363956 (risk allele 
t) (HR = 1.18, 95% CI 1.09–1.27, P=2×10−5, and HR = 1.13, 95% CI 1.06–1.21, P=2×10−4 
respectively). Neither SNP reached the threshold of significance in phase 1 to be selected for 
phase 2 of the EOC susceptibility GWAS, but in the combined phase 1 and 2 data both 
showed some evidence for susceptibility to EOC (OR=1.15, 95% CI 1.08–1.23, P=7×10−6, 
and OR=1.08, 95% CI 1.03–1.14, P=2×10−3 respectively). This association was stronger 
among ovarian cancers with serous histology (OR=1.22, 95% CI 1.13–1.31, P=1×10−7, and 
OR=1.14 95% CI 1.07–1.21, P=2×10−5 respectively). These effects were similar in analyses 
unadjusted for population stratification by principal components (data not shown). Risk 
allele frequencies of these SNPs in cases and controls by study are shown in Supplementary 
table 3.
In the phase 3 data there was no evidence for the association of rs1125436, rs8170 or 
rs2363956 with survival time (P=0.12, 0.85 and 0.25 respectively) with the effect of 
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rs1125436 in the opposite direction to phases 1 and 2 (data not shown). The direction of the 
survival effect was the same for rs8170 and rs2363956, with the effect size being larger in 
phase 1 compared to phase 2 and 3 (Supplementary figure 2b). In the combined analysis of 
all three phases, rs8170 and rs2363956 showed similar levels of association with survival 
(HR 1.11, 95% CI 1.04–1.17, P=5×10−4 and HR 1.09, 95% CI 1.04–1.14, P=6×10−4; Table 
1). The association with survival was not attenuated after adjusting for tumor grade, tumor 
stage, age at diagnosis and histology.
The phase 3 data, however, provided strong support for the association of rs8170 and 
rs2363956 with EOC susceptibility (Table 1). The association was considerably stronger 
when the analysis was restricted to serous cases and the association for both SNPs reached 
genome-wide significance in the combined data analysis of serous only cases (P=3×10−9 and 
4×10−11 respectively). These remained highly significant (P<10−9) after a conservative 
Bonferroni correction for three tests (all cases, serous cases, non-serous cases). There was 
little evidence of association with other histological subtypes (Table 2). No heterogeneity 
was seen in the OR of serous EOC risk or HR estimates for rs2363956 (Supplementary 
Figure 2a–b) or rs8170 (forest plots not shown) among studies for any phase. rs8170 and 
rs2363956 are separated by 4kB and are weakly correlated (r2 = 0.23). In multivariate 
models, the associations with susceptibility to serous cancer and survival could not be fully 
explained by either SNP alone.
The SNP rs8170 localizes to C19orf62, also known as MERIT40, a gene with 5 distinct 
transcripts described to date. Depending on the alternative splice form, it is either 
synonymous (K279K) or non-synonymous (S281R). It may also act as an exonic splice 
enhancer (http://pupasuite.bioinfo.cipf.es/). rs2363956 is a non-synonymous SNP (W184L) 
in ANKLE1. Both amino acids are neutral and nonpolar suggesting this is a conservative 
change. Three recent reports have described interactions between MERIT40 and a complex 
including BRCA1, RAP80, BRCC45 and CCDC989–11. MERIT40 appears to regulate the 
retention of BRCA1 at double strand DNA breaks and maintain stability of this complex at 
the sites of DNA damage. Our data suggesting that common genetic variants in MERIT40 
may predispose women mainly to serous ovarian cancer are also consistent with a similar 
subtype specificity associated with inactivating germline BRCA1 mutations12.
Common genetic variants can influence the expression of target genes through cis- and 
trans-regulation13. Because rs8170 and rs2363956 in MERIT40 and ANKLE1 respectively 
are located in the coding regions of these genes, we were able to evaluate cis-regulating 
expression by looking at both genotype associated expression and differential allelic 
expression, in 48 normal primary ovarian epithelial (POE) cell lines. We found no evidence 
of cis-regulated expression using either approach, although the power of these analyses was 
limited by the small sample size (Supplementary table 4 and Supplementary figure 3).
Array comparative genomic hybridization (aCGH) analysis was used to evaluate genomic 
alterations at the 19p13.11 locus in 105 high-grade serous ovarian cancers. Forty-six percent 
of tumors exhibit copy number gain/amplification of the p-arm of chromosome 19, with a 
peak of amplification in the region containing MERIT40 and ANKLE1 (Figure 1b and Figure 
1c). This suggests that target genes in this region are functionally activated during tumor 
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development. We compared the expression of MERIT40 and ANKLE1 between 48 POE cell 
lines and 23 ovarian cancer (OC) cell lines. Consistent with aCGH data, MERIT40 was 
significantly over expressed in OC cell lines compared to POE cell lines (P=5×10−9, Figure 
1d), but there were no differences in expression of ANKLE1 (p = 0.54) (Figure 1e). The data 
from The Cancer Genome Atlas (TCGA) Pilot Project analysis of 216 serous ovarian tumors 
also suggests that the expression of MERIT40 (but not ANKLE1) is elevated in the majority 
of EOCs compared to normal tissues (Figure 1f).
The data suggesting a role for MERIT40 in EOC development need to be treated with 
caution. The risk associated SNPs within MERIT40 and ANKLE1 may represent markers in 
linkage disequilibrium with the true functional variant(s) and target genes at this locus. 
Based on resequencing data from the 1000 genomes project (http://www.1000genomes.org/
page.php) there are fifteen SNPs perfectly correlated with rs8170 and nine SNPs correlated 
with rs2363956. Thus, genotyping of additional SNPs will be required to fine map this 
region in order to nominate optimal variants to investigate function. The peak of DNA copy 
number gain identified by aCGH analysis in primary EOCs spans approximately 3.5Mb 
(nucl. 16390797–19830868; build v37) and contains 119 genes. Within this, a 330kb region 
defined by the haplotype block harboring rs8170 and rs2363956 contains 14 known genes 
(Supplementary table 5). Gene expression data from TCGA suggests other candidate genes 
that could be the targets of amplification at this locus, some of which some are plausible 
cancer associated genes. These include NR2F6 (or EAR-2)14 which may be involved in 
regulation of disease progression in breast cancer, and TMEM16H, one of a family of trans-
membrane proteins that may be over-expressed in several cancers15.
We can only speculate on the possible functional role of MERIT40 in the initiation and 
development of serous subtype EOCs, if it is the target susceptibility gene at the 19p13 
locus. Any hypotheses would need to consider the apparent paradox suggested by our data 
that MERIT40 is over-expressed in EOCs, while BRCA1 is expected to show loss of 
function in its role in the double strand break (DSB) repair pathway. MERIT40 appears to 
act downstream of poly-ubiquitination of DNA (which occurs at all DSBs), and upstream of 
BRCA110. MERIT40 is necessary for BRCA1 assembly at γH2AX foci although BRCA1 is 
not usually a stable member of this complex9–11. Over-expression of MERIT40 may 
ectopically stabilize mutant BRCA1 protein into the assembled complex. Since MERIT40 
knockdown makes cells more sensitive to ionizing radiation10, 11, MERIT40 over-
expression could have the opposite effect, protecting cells with dysfunctional BRCA1 and 
DSB repair activity and enabling them to tolerate more DNA damage.
The association with survival was only apparent in phases 1 and 2, and did not reach 
genome-wide significance overall. The clear evidence of association with serous EOC risk 
suggests that the survival association could still be of interest, but further study will be 
required to clarify the magnitude of the association. We would not have detected the 
association at 19p13 with risk of EOC if SNPs had not been selected for phase 2 as a result 
of its association with survival time. The failure to detect an association with susceptibility 
may simply be the play of chance – the power in phase 1 to detect an odds ratio of 1.12 
(combined data estimate) at the P-value threshold required for a SNP to be taken into phase 
2 was 50 percent. It may also have been the result of other factors such as disease 
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heterogeneity - the association was stronger for serous EOC and our initial analysis of phase 
1 data (for selection of SNPs for Phase 2) was based on cases of all histological types. 
Furthermore, the majority of the phase 1 cases were prevalent and, if the association of this 
locus with survival time is real (but small), this would bias the susceptibility association 
towards the null.
These data add to a growing list of genetic loci with common susceptibility alleles for EOC. 
Our data suggesting that the BRCA1 interacting gene MERIT40 may be the gene underlying 
the genetic associations add weight to the significance of the 19p13 locus for susceptibility 
in EOC. This is further emphasized by the finding of Antoniou et al. in the accompanying 
article16 that genetic variants in this region appear to modify the risks of breast cancer in 
individuals carrying germline BRCA1 mutations.
Methods
Study design
The ovarian cancer case-control studies that participated in phases 1, 2 and 3 are 
summarized in Supplementary table 2. Phase 1 comprised invasive epithelial ovarian cancer 
cases from UK and genotype data of UK controls from GWAS of other phenotypes. Phase 2 
comprised ten case-control studies from the Ovarian Cancer Association Consortium. Phase 
3 comprised 16 case-control studies from the OCAC and five case-only studies. All studies 
provided data on age at diagnosis and date of blood draw, self-reported ethnic group and 
histological subtype. Tumor histology was collected for all cases based on pathology reports 
or central pathological review and was categorized according to the World Health 
Organization classification system for ovarian cancer17.
Genotyping
Genotyping for phase 1 cases was conducted using the Illumina Infinium 610K array at 
Illumina Corporation. Existing data from two sets of controls, genotyped on the Infinium 
550k array, were used in phase 1 analyses: the Welcome Trust Case-Control Consortium 
1958 birth cohort and a national colorectal control study. All cases were from the UK and 
confirmed as invasive epithelial ovarian cancer. Genotyping the phase 2 studies was 
conducted using a custom Illumina iSelect array at Illumina Corporation.
For four phase 3 studies (TOR, NCO, MAY, MOF) genotype data were available from an 
independent, ongoing GWAS study that also used the Illumina Infinium 610K platform. 
Genotyping and QC were performed at the Mayo Clinic genotyping shared resource. 
deCODE ovarian cancer cases were assayed by single SNP genotyping on the Centaurus 
(Nanogen) platform and controls were from a GWAS using the Human Hap300 and 
HumanCNV370-duo Bead Arrays. The SNP rs2363956 was genotyped using ABI Taqman 
for five of the phase 3 case-only studies (LAX, PVD, SCO, YAL and additional cases from 
HOP). The remaining phase 3 studies were genotyped using Sequenom iPlex. Quality 
control procedures for all study phases are described in the supplementary materials.
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Population stratification
We used the program LAMP18 to assign intercontinental ancestry to phase 1 samples based 
on the HapMap genotype frequency data for European, African and Asian populations 
(release no.22). LAMP was also used to assign ancestry to the Phase 2 samples using the 
HapMap data on European (CEU), African (ASW), East Asian (JPT-CHB-CHD), Mexican 
(MEX) and Indian (GIH). Subjects with less than 90 percent European ancestry were 
excluded. For both the phase 1 and 2 samples, we used AIMs to calculate principal 
components for the subjects of European ancestry. The first principle component explained 
0.42 percent of the variability and was included as a covariate in subsequent association 
analyses. Subsequent principal components were not included as they explained less 
variability and there was little difference in their eigenvalues. In the phase 3 dataset, we 
excluded samples if their self-reported ethnicity was other than non-Hispanic white.
Imputation
We imputed missing genotype data for all the common variants in the HapMap for phase 1 
samples in order to increase genome coverage. We used an in-house method that combines 
the features of fastPHASE19 and IMPUTE20 to impute the ungenotyped or missing SNPs, 
using the phase 2 HapMap data (CEU) which contains phased haplotypes for 60 individuals 
on 2.5 million SNPs. For each imputed genotype the expected number of minor alleles 
carried was estimated (weights). Genotyped SNPs were assigned weights of 0, 1 or 2 (actual 
number of minor alleles carried). We estimated the accuracy of imputation by calculating 
the estimated r2 between the imputed and actual SNP. SNPs with r2 < 0.64 were excluded (n 
= 152,401) leaving a total of 2,563,972 SNPs for phase 1 analysis.
Tests of association
In the analysis of the phase 1 and phase 2 data the effect of each SNP on time to all-cause 
mortality after EOC diagnosis was assessed using Cox regression stratified by study and 
modeling the per-allele effect as log-additive. The Cox proportional hazards assumption was 
evaluated by inspection of standard log-log plots. Individual level data for the deCODE 
study were not available and so for the analysis of the phase 3 data and for the combined 
analyses, each study was analyzed separately and the results pooled by estimating an 
average of the study specific loge hazard ratios with each weighted by the inverse of its 
variance. Because the EOC cases showed a variable time from diagnosis to study entry, we 
allowed for left truncation with time at risk starting on date of diagnosis and time under 
observation beginning at the time of study entry. This generates an unbiased estimate of the 
hazard ratio provided the Cox proportional hazards assumption is correct21. The analysis of 
phase 1 data was right censored at 10 years after EOC diagnosis. In subsequent analyses, we 
right censored at 5 years after diagnosis in order to reduce the number of non-EOC related 
deaths. We used logistic regression to test for association between genotype and case-control 
status. For phase 1 and 2 data we adjusted for study phase and study by including phase and 
study specific indicators in the model. For phase 3 data we analyzed each study separately 
and then pooled the results using an inverse-variance weighted average of the study specific 
loge odds ratios.
Bolton et al. Page 6
Nat Genet. Author manuscript; available in PMC 2011 June 29.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Array Comparative Genomic Hybridisation (aCGH) Analysis
aCGH analysis was performed using a whole genome tiling path microarray (http://
www.instituteforwomenshealth.ucl.ac.uk/academic_research/gynaecologicalcancer/trl/
arrayfacility) consisting of 32,450 BAC clones22. Regions containing >80 percent 
neoplastic cells were micro-dissected from formalin fixed paraffin embedded tumor tissue 
sections, and DNA extracted by proteinase K digestion. Tumor DNA and matching 
peripheral blood DNA were amplified using the GenomePlex whole genome amplification 
kit (Sigma) and fluorescently labelled using the BioPrime Total Kit (Invitrogen). 
Microarrays were co-hybridised with the labelled DNA as described previously23, scanned 
using a Scanarray Express laser scanner (Perking Elmer), and spot signal intensities 
extracted using BlueFuse (BlueGnome). Raw data were analysed using R and the 
Bioconductor packages MANOR, LIMMA, DNAcopy and CGHcall as described elsewhere. 
BAC clone locations were derived from NCBI Human Genome build 36 (HG18).
Gene expression analysis in POE and OC cell lines
Normal, primary ovarian epithelial (POE) cell lines were established from brushings of 
normal ovaries of patients undergoing total hysterectomies at University College London 
Hospital (UCLH), UK. All ovaries were histologically confirmed as free of disease. UCLH 
ethical committee approval was given for the collection and analysis of all patient samples. 
Short-term cultures of POE cells were established as previously described24. The non-
neoplastic status and epithelial (non fibroblastic) nature of cells was confirmed by staining 
for the markers CA125, CK18, FVIII and FSP. RNA was extracted from POE and OC cell 
lines (Supplementary table 4) using RNAeasy Mini Kits (QIAgen). Reverse transcribed 
(RT) RNA was analyzed for candidate gene expression by semi-quantitative real-time PCR 
using the Applied Biosystems 7900HT genetic analyzer. Gene expression was normalized 
against 2 endogenous controls Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
β-actin. Real time expression data were analyzed using the comparative Delta-Delta Ct 
method. The expression values for genes in all cell lines that are given are relative to either 
the lowest or highest expression of a POE cell line, normalized against GAPDH and β-actin. 
Differences in the relative expression of each candidate gene between EOC and POE cell 
lines were assessed using the nonparametric two-sided Wilcoxon Rank sum test using R. For 
allele specific expression analysis, gene expression was calculated relative to the average 
expression of the common homozygotes for each candidate SNP normalized against the 
expression of the endogenous control genes. Wilcoxon Rank sum tests were used to assess 
the difference in expression between common homozygotes, heterozygotes and rare 
homozygotes.
Differential allelic expression analysis in POE cell lines
For each SNP, 8ng of cDNA from the heterozygous POE cell lines (10 for rs8170 and 15 for 
rs2363956) were analyzed by real time RT_PCR using Taqman custom genotyping assays 
(Applied Biosystems). Genomic DNA extracted from lymphocytes from two heterozygous 
individuals was used for a standard curve to adjust for dye bias as there would be equal 
copies of each allele. All samples were analyzed in triplicate. Differential allelic expression 
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was determined from the log2 ratio of the VIC allele / FAM allele with a cut-off of 
log2(1.20)=0.263 as described previously13.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Genomic and transcript analysis of the MERIT40 and ANKLE1 genes in the 19p13 
ovarian cancer susceptibility region
(a) Genomic architecture of the 19p13.11 region containing the two SNPs most significantly 
associated with EOC risk (rs8170 and rs2363956). SNPs are located with respect to genes 
within this region. rs8170 is located in MERIT40 and rs2363956 is located in ANKLE1. (b) 
Whole genome array comparative genomic hybridization (aCGH) analysis of 105 serous, 
invasive ovarian cancers displays the range of copy number changes throughout the genome, 
along the length of each chromosome. Green = frequency of copy number gain; red = copy 
number loss. (c) Higher resolution aCGH map of chromosome 19 indicates that this 
chromosome is frequently amplified in EOCs with an amplification peak at the 19p13.11 
susceptibility locus (blue line); 48/105 tumors (46%) showed copy number gain at 19p13.11 
compared to 2/105 tumors (2%) that showed copy number loss. (d & e) Transcript 
expression of MERIT40 and ANKLE1 in 48 normal primary ovarian epithelial (POE) cell 
lines compared and 23 OC cell lines detected using real time RT-PCR. For each gene, 
transcript expression is normalized against β-actin; genes expression normalized against a 
second endogenous control, GAPDH, showed similar trends (Supplementary figure 4). 
MERIT40 expression is significantly higher in OC cell lines compared to POE cells (d), but 
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there was no difference in ANKLE1 expression between OC and POE cells (e). (f) 
Expression data from the Cancer Genome Atlas Project (http://cancergenome.nih.gov) for 
MERIT40 and ANKLE1 genes analyzed in 216 serous EOCs. The graph shows proportion of 
tumors that show loss or gain of expression with >0.5 fold change relative to pooled 
‘normal’ samples.
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